anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This study adopted a single-center, single-arm, single-dose combined multiple-dose administration, and dose-escalation clinical trial design to evaluate the safety, tolerability and preliminary effectiveness of UCMSCs in the treatment of patients with decompensated liver cirrhosis. Patients were recruited into three different dose groups, and 12 subjects were enrolled in each group. The subjects of each group will receive 0.5×10\^6 cells/kg, 1.0×10\^6 cells/kg, and 2.0×10\^6 cells/kg respectively. According to the principle of dose escalation, subjects preset to low-dose will receive the administration first. Each group will receive only one corresponding dose for safety and tolerability check. The subjects will be observed for 21 days after the initial dose due to limited proliferation or differentiation potential and relatively low immunogenicity of mesenchymal stem cell products. The safety measures will be discussed by the Data Safety and Monitoring Board (DSMB) to determine whether subjects who have received a single dose will proceed with subsequent injections. Once all subjects in the lower-dose group have completed the initial administration and observed for 21 days. The DSMB will decided whether to proceed with the next-dose group. All subjects will receive routine drug treatment during the study. Primary endpoint: incidence and severity of cell therapy related adverse events from the beginning of treatment to the end of the follow-up. Secondary end point of the study includes: the change in Model For End-Stage Liver Disease (MELD) score of the subjects from baseline, at 1, 3, 6 and 12 months after the last administration; the overall survival rate at the 12th month after the last administration; Changes in liver function compared with baseline at 1, 3, 6 and 12 months after the last administration; changes of child Pugh score compared with baseline at 1, 3, 6 and 12 months after the last administration; and the change of Karnofsky Performance Status Scale (KPS) score from baseline at 1, 3, 6 and 12 months after the last administration.
The invention relates to an easy-going medicated wine. Specifically, the easy-going medicated wine is prepared through soaking drugs in 75% alcohol or high-degree white spirit. The easy-going medicated wine has the effects of reinforcing the kidneys to strengthen Yang and strengthening the muscles and bones; all the drugs are used in a combined manner, the compatibility is ingenious, the force is specific, and the effect is great. The medicated wine disclosed by the invention is used for soothing the liver and relieving depression and nourishing the blood and invigorating the spleen, can be used for keeping people energetic and prolonging lives of people, and is particularly applicable to old and weak people. By using the medicated wine, people can enjoy wine drinking during drinking, and meanwhile, the medicated wine plays roles in keeping in good health, caring health and treating diseases. The medicated wine has important practical significance in the prevention and treatment and health care of human bodies.
Patients receive oral SAHA once daily for 2 days prior to surgery and then on the day of surgery. Patients also receive bortezomib IV on the day of surgery. After receiving the 3rd dose of SAHA, patients undergo surgery to remove the tumor. Beginning at least 7 days after surgery, patients receive SAHA and bortezomib as in stratum 1.
Binge eating disorder (BED) is a severe eating disorder characterized by recurrent episodes of binge eating, where control over eating is lost and huge amounts of food are eaten within a short period of time. Hence, weight issues are often inevitable and overweight is common, as are social, mental as well as physical problems.

The etiology of binge eating disorder is an interplay of neurobiological and environmental factors. Overall pathological eating, including grazing, external, emotional or restrictive eating, is associated with binge eating, and so is dysregulation in the reward center, impairment of executive functions and emotion regulation. The investigators suggest that it is possible to identify specific profiles driving binge eating, depending on the severity of these dimensions, and that these profiles might predict the outcome of treatment. The investigators also suggest that early change in general eating pattern, emotion regulation, and depressive symptoms is associated with binge eating outcome. These assumptions will be tested in a sample of adults in treatment for BED at one of three sites using questionnaires before, during and after treatment, incl. 6- and 12-month follow-ups.
Caregivers provide critical support for older adults managing multiple chronic conditions (MCCs), but few studies describe the assistance caregivers provide or identify factors influencing their provision of support. We conducted qualitative interviews with 25 caregivers to older adults with MCCs to describe caregivers' roles and identify the factors that influence caregivers' ability to carry out these roles. Transcripts were analyzed using the Framework Method. Caregivers supported the management of MCCs in several ways, including monitoring conditions, communicating with clinicians, and tracking health information. Disagreement, or conflicted relationships, between caregivers and older adults over health and behaviors influenced the provision of support, resulting in less involved and less effective caregivers. Caregivers in conflicted relationships were more challenged by resistance from older adults. Greater agreement, or collaboration, between caregivers and older adults resulted in more involved and effective caregivers. Addressing health-related conflict may enhance caregivers' capacity to support older adults with MCCs.
This study aimed to investigate the impact of occupational pushing and pulling combined with improper working posture on work-related low back pain (LBP) among workers. A web-based survey was conducted in 2022 to collect data from 15,623 workers, who were categorized into proper and improper working posture groups. Multiple logistic regression analysis was used to analyze the association between pushing and pulling loads and LBP in each group. In the proper working posture group, the odds ratios (ORs) of LBP for workers who pushed and pulled were not significantly different compared with those of no-handling workers. However, in the improper working posture group, the ORs of LBP were significantly greater among workers who pushed and pulled compared with those of no-handling workers, and this association became stronger with increasing weights. Therefore, improper working posture combined with pushing and pulling were strongly associated with LBP among workers, particularly with heavier weights.
To maintain an improved lifestyle.SOLUTION: A system 1 is formed of a measurement device 10, a terminal device 20, and a processor 30. The terminal device 20 and the processor 30 are connected by a network 40. The measurement device 10 measures a part or the whole of a living body, and provides a living-body measured value. The processor 30 processes the living-body measured value and provides at least a score. The terminal device 20 outputs the score. The score reflects a first improvement value and a second improvement value of the living-body measured value. The time when the first improvement value is reflected is before a predetermined point of the period of time of measuring a living body. The time when the second improvement value is reflected, on the other hand, is the predetermined point or after the predetermined point.SELECTED DRAWING: Figure 2
The invention discloses a microneedle array which contains lipid modifying carrier and is used for a vaccine adjuvant transmission system. The microneedle array comprises a substrate and a plurality of microneedles fixed on the substrate, wherein the substrate is composed of saccharides, povidone, cellulose, or starch auxiliary materials; each microneedle comprises lipid A modifying carrier, the auxiliary materials (excipients) and vaccine ingredients; the lipid A modifying carrier can be lipidosome, lipid, micro-capsule or nanoparticle, and the like; the vaccine ingredients mainly refer to causative agent antigen proteins. Compared with the existing vaccine preparations, the lipid A-modified lipidosome microneedle array vaccine adjuvant transmission system can contain different vaccine ingredients to form vaccines aiming to different pathogens and therefore has a wide application scope. Biodegradable materials are selected and therefore the safety is high. The microneedle array vaccine adjuvant transmission system is a solid preparation which is high in stability and convenient to inoculate. Inoculation can be completed by a user self through oral mucosa, the vaccine can be prevented from running away along with saliva, and a body can be induced to establish mucosal immunity.
This is a randomized, single-blind, sequential group, ascending PER977 reversal dose study in healthy volunteers. Subjects will be randomized in a 4:1 ratio to receive either PER977 or placebo. All subjects will receive a single dose of edoxaban 60 mg on Days 1-4. On Days 3 and 4, study drug will be administered 3 hours following edoxaban. Beginning with Cohort 2, study drug will be administered only to those subjects with a minimum increase in whole blood clotting time \>25% above baseline.

Pharmacokinetic assessment of PER977 and tis metabolite, and edoxaban and its metabolite will be performed. Pharmacodynamic assessment of WBCT and Point of Care prothrombin time will be performed. Safety will be assessed throughout the study.
PURPOSE:To obtain a health drink, by semi-drying the stalk of fatsia, the green twig and leaf of spindle tree and the leaf of KUMAZASA (Sasa albo-marginata), mixing the above three components after washing, steaming the mixture in a steaming pan, cooling spontaneously, storing and fermenting in a fermentation chamber, and completely drying the fermentation product. CONSTITUTION:The stalk of grown fatsia is semi-dried, crushed to a proper size and washed. Green twig or leaf of spindle tree is dried in the shade in semi-dried state, crushed to a proper size, and washed. Leaf of KUMAZASA is dried in the shade in semi-dried state, crushed to a proper size and washed. The above three components are mixed together, steamed in a steaming pan, cooled spontaneously, stored and fermented in a chamber, dried completely in the sun, and cut or finely pulverized to obtain the objective health drink. The component of fatsia is effective mainly to strengthen the function of pancreas, that of the spindle tree is effective to strengthen the function of liver and the dissolution of calculus, and that of KUMAZASA has anti-inflammatory, diuretic and hypotensive effects to various internal organs.
Strong patient-provider communication and vigilant home-based monitoring can be critical elements of successful chronic disease management. Among CHF patients, automated clinical data acquisition via the telephone can improve insight into inappropriate use of medications and onset of fluid overload or edema - indicating deteriorating heart function (notably worsening ejection fraction). Routine, timely monitoring of this data can direct a nurse case manager to the subset of CHF patients likely to benefit from a clinic visit, evaluation, diagnosis, and counseling. This should result in: significantly increased medication compliance, significantly lower emergency department (ED) visits and hospital admissions (both those related to CHF and other conditions related to diminished physical capacity of patients with CHF), and improved physical function.

This study is intended to answer three questions. First, do potentially avoidable acute events (measured by ED visits and hospital admissions) decrease when CHF management is accompanied by systematic telephone-based monitoring as compared with usual care? Second, does medication compliance improve when CHF management is accompanied by systematic telephone-based monitoring as compared with usual care? Third, does perceived health status (physical and emotional function) improve when CHF management is accompanied by systematic telephone-based monitoring as compared with usual care?
Cardiac hypertrophy is a key factor driving heart failure (HF), yet its pathogenesis remains incompletely elucidated. Mettl1-catalyzed RNA N7-methylguanosine (m7G) modification has been implicated in ischemic cardiac injury and fibrosis. This study aims to elucidate the role of Mettl1 and the mechanism underlying non-ischemic cardiac hypertrophy and HF. It is found that Mettl1 is upregulated in human failing hearts and hypertrophic murine hearts following transverse aortic constriction (TAC) and Angiotensin II (Ang II) infusion. YY1 acts as a transcriptional factor for Mettl1 during cardiac hypertrophy. Mettl1 knockout alleviates cardiac hypertrophy and dysfunction upon pressure overload from TAC or Ang II stimulation. Conversely, cardiac-specific overexpression of Mettl1 results in cardiac remodeling. Mechanically, Mettl1 increases SRSF9 expression by inducing m7G modification of SRSF9 mRNA, facilitating alternative splicing and stabilization of NFATc4, thereby promoting cardiac hypertrophy. Moreover, the knockdown of SRSF9 protects against TAC- or Mettl1-induced cardiac hypertrophic phenotypes in vivo and in vitro. The study identifies Mettl1 as a crucial regulator of cardiac hypertrophy, providing a novel therapeutic target for HF.
Identifying high-risk patients for perioperative treatment and decision-making remains a challenge due to difficulty in reliably estimating morbidity and mortality risks. Assessing surgical risk helps allocating resources, obtaining informed consent, and making shared decisions with a multidisciplinary team (MDT). Multimorbidity is increasing globally in an ageing population with a growing burden of chronic diseases. It has been shown that high-risk non-cardiac surgical patients suffer disproportionally from perioperative complications. Preoperative mortality risk calculators are available and may help to identify high-risk non-cardiac surgical patients already before surgery, triggering efforts to lower the burden of possible complications, e.g., by extended monitoring or specified treatments. A systematic review suggested a significant risk of bias in developing current preoperative risk calculators due to lack of external validation, highlighting the need for enhanced performance and reliability to ensure their effectiveness in clinical practice. Low reliability and performance may, despite their general availability, be why that preoperative risk calculators are not yet consistently used in clinical practice. For daily clinical use, good predictive performance, low inter rater variability and user friendliness are essential. Discrepancies in predictor measurements can cause miscalibration, changes in discriminatory ability, and overall accuracy, leading to clinically relevant variability in risk calculator results. Previous studies have shown that physicians must trust a mortality risk calculator before utilization. High-risk patients suffer especially from complications, and it has been shown that the complications often result in death perioperatively. Therefore, adequate preoperative calculation of mortality risks and early recognition of high-risk non-cardiac surgical patients could benefit from reliable preoperative risk calculation. These high-risk patients can then be discussed in a preoperative multidisciplinary discussion to lower complications and perioperative deaths.

The current study evaluated the inter-rater reliability of calculating preoperative mortality risk scores for high-risk non-cardiac surgical patients in clinical practice among five anesthesiologists. The hypothesis was that the available risk calculators would show moderate to good reliability. For this purpose, five anesthesiologists used the following three risk calculators: the preoperative score to predict postoperative morbidity \[POSPOM, the American College of Surgeons surgical risk calculator, and the surgical outcome risk tool \[SORT\].
PN401 is given on Days 1-3 weekly for six weeks; 5FU and leucovorin are given on Day 1 weekely for six weeks; followed by two weeks of rest. Continued in 8 week cycles until one of the criteria for removal from treatment is met.
A network apparatus system and method of use adapted for viewing, illustrating, consulting and collaborating on medical images and saving images and illustrations in acceptable DICOM format. Specifically, a Consultant Client or a plurality of Consultant Clients having the capability to view still and streaming video medical images, then illustrating over those images with the ability to save those images. In the present invention the illustration images automatically fading and disappearing after a preset predetermined amount of time, without user input. Also a Collaborator Client, a person user or a plurality of Collaborator Clients having the ability to remotely view streaming or still medical images and illustrating over those images. The Collaborator Clients can draw, telestrate and annotate over those images with the ability to save those images and videos, and save the drawings, telestrations and annotations provided these input illustrations are visible when saved. The Collaborator Client also has the ability to work in partnership with other Collaborator Clients, each Collaborator Client viewing the same medical image and each illustrating on the image and each being able to view all users illustrations and medical image simultaneously, and all illustrations fading and disappearing without the users in session input.
The invention provides a nutrition preparation for preventing and treating disease of respiratory system and a preparation method thereof. The nutrition preparation is composed of, by weight, 10-50 parts of a licorice extract, 5-25 parts of tremella polysaccharide, 5-25 parts of platycodin, 1-10 parts of a dark plum extract, 1-10 parts of a lophatherum herb extract and 1-20 parts of a perilla extract. The nutrition preparation is obtained by mixing the above ingredients. All the ingredients of the nutrition preparation are originated from food, are safe and have no toxic or side effect. Through synergistic effect of all the ingredients, the nutrition preparation has a remarkable effect of preventing and treating disease of respiratory system. The preparation method is simple and meets requirements of large-scale industrial production.
PURPOSE:To prepare a health nutrient drink without forming a precipitate even on storage for a long term and loss of active constituents, by adding pectin extracted from a beet pulp to a filtrate obtained from a culture fluid of fungi belonging to the genus Grifola. CONSTITUTION:Fungi of the genus Grifola, e.g. Grifola albicans, Imaz. or Grifola frondosa S.F. Gray, are inoculated into a culture medium consisting of an edible substance nontoxic to the human body, and cultivated at 20-30 deg.C under aerobic conditions for 10-20 days. The resultant culture is sterilized under heating, and the fungal cells are filtered to give a filtrate from the culture fluid, and the filtrate is then mixed with pectin extracted from a beet pulp in an amount in the range of 0.5-1.5vol% (w/v) and if desired further sugar, an organic acid or various seasonings.
The study is designed to obtain tumor samples from patients undergoing clinically indicated surgical resection of a brain tumor or primary non-CNS tumor after infusion of 13C-glucose, 13C-acetate or 13C-glucose and 13C-acetate. Patients with a brain mass identified on brain imaging and who need surgical resection of the mass will be eligible for this metabolism study. Eligible study patients will be screened, recruited, and enrolled at UT Southwestern Medical Center in the Harold C. Simmons Comprehensive Cancer Center, University Hospital - Zale Lipshy and University Hospital - St. Paul, Children's Medical Center of Dallas as well as at Parkland Health and Hospital System. We will consent 60 patients, including projected screen failures and early withdrawals, and anticipate that we will study 25 patients in this clinical protocol. Once enrolled, patients will undergo a series of preoperative brain imaging studies including 3T MRI with Diffusion Tensor Imaging (DTI) and 1H-MR spectroscopy, 7T MRI and a brain 18FDG-PET scan within 7-14 days of the scheduled operation. Of these studies, only the 3T MRI is standard of care. The DTI and 1H-MR spectroscopy are additional scanning sequences that are being done for research purposes. Similarly, the 7T MRI and the 18FDG-PET are being done for research purposes only. On the day of surgery, the patient will have a peripheral IV started while waiting in the preoperative holding area and a 20% solution of either \[U-13C\]glucose and/or \[1,2-13C\]acetate (to be determined for each individual patient by the PI) will be infused at a rate of 4g/hr for a maximum of 4 hours. During the infusion period, 4 timed blood samples will be collected for NMR analysis of 13C-glucose in the blood. The infusion will continue until the tumor has been resected and samples have been collected and flash frozen for 13C-NMR spectral analysis and molecular analyses. The infusion and tumor collection for 13C-NMR analysis is being done for research purposes only. However, the remainder of the neurosurgical operative and post-operative procedures will be followed according to standard practice. The patient will be seen 10-14 days after surgery for a follow up visit at which time an assessment of adverse events will be performed. Thereafter, every 6 months for 5 years or until death, the patient will be contacted and data regarding treatment, responses, and tumor progression will be collected for correlative analysis.
Sarcopenia is becoming a severe global public health concern as the world's elderly population grows. Sarcopenia is characterized by muscular mass and strength loss, as well as impaired physical performance, and it is frequently connected with negative health outcomes such as falls. Falls are a primary cause of death in older individuals and must be addressed. Sarcopenia is currently diagnosed clinically using three primary technologies: imaging technology, precision medicine, and machine learning. In this study, the investigators will use previously collected data from nearly 200 community-dwelling subjects, including medical history, biochemistry, body composition, balance and gait, electromyography, and functional performance, to extract the characteristics and classification of sarcopenia using machine learning techniques such as empirical mode decomposition technology and decision tree algorithms. The investigators intend to offer clinically proven and effective interventional strategies to prevent, stabilize, and reverse sarcopenia.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In clinical trials, most of the reported side effects were mild to moderate in severity and were reversible upon discontinuation of the drug. Potentially serious adverse reactions of angioedema and cholestatic jaundice were reported. Approximately 0.7% of the patients (adults and pediatric patients) from the 5-day multiple-dose clinical trials discontinued azithromycin therapy because of treatment-related adverse reactions. In adults given 500 mg/day for 3 days, the discontinuation rate due to treatment-related adverse reactions was 0.6%. In clinical trials in pediatric patients given 30 mg/kg, either as a single dose or over 3 days, discontinuation from the trials due to treatment-related adverse reactions was approximately 1%. Most of the adverse reactions leading to discontinuation were related to the gastrointestinal tract, e.g., nausea, vomiting, diarrhea, or abdominal pain. [see Clinical Studies (14.2)]